ZYUS Life Sciences Corporation announced the issuance of a U.S. patent for a novel cannabichromene (CBC) formulation aimed at managing chronic and neuropathic pain without opioids. This patent strengthens their intellectual property portfolio and supports ongoing clinical research for their second drug candidate targeting conditions like diabetic and cancer-related neuropathies. The patent complements their existing lead drug, Trichomylin® softgel capsules, and paves the way for potential clinical trials and regulatory approval in the U.S. This development highlights ZYUS' commitment to innovative, non-opioid pain therapies addressing significant unmet medical needs.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...
The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for se...
Law Offices of Howard G. Smith has announced upcoming deadlines for investors to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege that the compani...
The global waterborne epoxy resins market, valued at $4.98 billion in 2024, is projected to grow at a CAGR of 6.03% to $8.51 billion by 2034. This growth is fueled by strict international regulations targeting volatile organic compound emissions and ...
NEWMEDIA.COM highlights that top ecommerce web design agencies prioritize conversion and scale over just appearance, addressing the nearly 70% cart abandonment rate largely caused by fixable user experience issues like slow pages and complicated chec...
